Prolyl-4-Hydroxylase α Subunit 2 as a Novel Potential Biomarker for Predicting the Prognosis of Epithelial Ovarian Carcinoma

Figures & data

Figure 1 The up-regulation of P4HA2 in clinical samples of patients with EOC. (A) The normal ovarian tissues and EOC tissue were pathologically confirmed using H&E staining. Representative images were shown at 200× magnification (scale bar, 100 μm) and 400× magnification (scale bar, 50 μm). (B) The expression of P4HA2 in normal ovarian tissues and EOC tissue were detected using IHC staining. Representative images were shown at 200× magnification (scale bar, 100 μm) and 400× magnification (scale bar, 50 μm). (C) Semi-quantitative P4HA2 expression in normal ovarian tissues and EOC tissue by staining score.

Abbreviation: EOC, epithelial ovarian cancer.

Figure 2 The up-regulation of P4HA2 in EOC patients from Oncomine database. (A) The expression of P4HA2 mRNA in Adib ovarian dataset. (B) The expression of P4HA2 mRNA in Hendrix ovarian dataset.

Abbreviation: EOC, epithelial ovarian cancer.

Table 1 Association Between P4HA2 Expression and Clinicopathologic Characteristics of EOC Patients

Characteristics	Cases	P4HA2 Expression
		Low Expression	High Expression	P-value
Age (years)
<50	78	47	31	0.956
≥50	89	54	35
Clinical stage
I–II	59	42	17	0.036
III–IV	108	59	49
Grade
G1	41	34	7	<0.001
G2-G3	126	67	59
Clinical histology
Serous	104	59	45	0.203
Others	63	42	21
Residual disease (cm)
≤1	66	47	19	0.022
>1	101	54	47

Table 2 Cox Regression Analysis for Overall Survival in Patients with EOC

Characteristics	Univariate Analysis			Multivariate Analysis
	HR	95% CI	P-value	HR	95% CI	P-value
Age (<50 vs ≥50 years)	1.387	0.912–2.110	0.126	1.485	0.948–2.324	0.084
Clinical stage (III–IV vs I–II)	1.514	1.236–1.855	<0.001	1.29	1.017–1.636	0.036
Grade (G2-G3 vs G1)	0.925	0.720–1.190	0.546	0.88	0.673–1.151	0.352
Clinical histology (Serous vs others)	0.976	0.767–1.242	0.842	0.891	0.661–1.201	0.450
Residual disease (>1 vs ≤1 cm)	1.858	1.392–2.478	<0.001	1.704	1.268–2.289	<0.001
P4HA2 expression (High vs low)	4.495	2.258–8.948	<0.001	3.35	1.619–6.934	0.001

Figure 3 P4HA2 expression is associated with poor prognosis in patients with EOC. (A and B) Kaplan–Meier curves of progression-free survival (A) and overall survival (B) in EOC patients categorized by P4HA2 expression; (C and D) the Kaplan–Meier plotter platform (http://www.kmplot.com) resulted that patients with the high P4HA2 expression was significantly associated with short progression-free survival (C) and poor overall survival (D) in EOC; (E) The P4HA2 expression in different pathological types. (F and G) Kaplan–Meier curves of progression-free survival (F) and overall survival (G) in HGSOC patients categorized by P4HA2 expression.

Abbreviations: EOC, epithelial ovarian cancer; HGSOC, high-grade serous ovarian cancer; MOC, mucinous ovarian cancer; EnOC, endometrioid ovarian cancer; OCCC, ovarian clear cell carcinoma.

Figure 4 The relationship between P4HA2 with COL1A1. (A) The expression of COL1A1 mRNA in TCGA ovarian dataset; (B) the correlation analysis between P4HA2 and COL1A1 expression was analyzed using Spearman correlation in the GEPIA database; (C and D) the Kaplan–Meier plotter platform (http://www.kmplot.com) resulted that patients with the high COL1A1 expression was significantly associated with short progression-free survival (C) and poor overall survival (D) in EOC.

Abbreviation: EOC, epithelial ovarian cancer.